本文轉載自原廠電子報: ACROBiosystems | www.acrobiosystems.com
|
Free Sample Available
|
|
|
Learn New Publications of Anti-SLAMF7 CAR-T Cell Therapy, and Try PE- SLAMF7 Protein for Free!
|
|
|
On October 8, 2020, a study has been published in Nature communications indicated that T cells expressing a CD28-containing anti-SLAMF7 CAR and a suicide switch capable of eliminating CAR T cells on demand exhibit increased anti-tumor activity and decreased toxicity.
|
|
|
Researchers from University of California-Los Angeles find that BCMA/CS1 single-chain bispecific CAR-T cells exhibit superior CAR expression and function compared to T cells that co-express individual BCMA and CS1 CARs. The BCMA/CS1 bispecific CAR presents a promising treatment approach to prevent antigen escape in CAR-T cell therapy against MM.
|
|
|
The newly launched PE-labeled SLAMF7 protein (Cat. No. SL7-HP2H3)
at ACROBiosystems is a powerful tool for detecting anti-SLAMF7 CAR expression by one step staining with high sensitivity and high specificity. Besides PE-labeled version, FITC and Biotin-labeled SLAMF7 proteins are also available. The bioactivity of these products has been verified by flow cytometry. |
|
|
Validation Data by FACS
Product：PE-Labeled Human SLAMF7 Protein, His Tag
Cat. No：SL7-HP2H3
|
|
|
|
|
1e6 of the anti-SLAMF7 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer of PE-Labeled Human SLAMF7 Protein, His Tag (Cat. No. SL7-HP2H3)
and negative control protein respectively, PE signals was used to evaluate the binding activity (QC tested). |
|
|
Product：FITC-Labeled Human SLAMF7, His Tag
Cat. No：SL7-HF2H7
|
|
|
|
|
2e5 of Anti-SLAMF7 CAR-293 cells were stained with 100 μL of 10 μg/mL of FITC-Labeled Human SLAMF7, His Tag (Cat. No. SL7-HF2H7
) and negative control protein respectively, FITC signal was used to evaluate the binding activity (QC tested) |
|
|
Product list
Molecule：SLAMF7
|
|
|
PepTalk 2021: The Protein Science and Production Week
|
|
|
Time: Jan 19-21, 2021, PST
PepTalk: Where the Protein Science Community Comes To Life
While a lot has changed since PepTalk was launched in 2001, the number one goal has always been the same – to serve and unite the biotherapeutics community.
As Peptalk celebrates 20th year, a fully integrated virtual event for 2021 will continue to serve as a content hub for the latest research and biotherapeutics developments, provide a 1:1 networking platform, offer an interactive exhibit hall, live Q&A sessions, breakout |
|
|
ACRO’s talk
Day One: January 19 at 1:50 p.m. PST.
Tittle: When science gets lucky: Targeting Spike protein for effective vaccine and therapeutics against SARS-CoV-2
Program/Track: Protein &Antibody Therapeutics – Hindsight Is 2020: Application of Accelerated Vaccines and Therapeutics Development
Highlights:
The global SARS-CoV-2 pandemic has challenged healthcare systems around the world even after almost a year of efforts to contain spread and treat patients. One of the brightest spots has been the record pace of scientific and medical discoveries that have led to generation of promising vaccines and antibody therapeutic against SARS-CoV-2 centered on Spike protein (S). ACROBiosystems is proud to support development of vaccines and therapeutics against COVID-19. |
|
|
|
|
Product Development Scientist
at ACROBiosystems
|
|
|
We are doing a raffle for our llamas. Click here
to enter our raffle and have the chance to win an adorable & plushy Llama! We will contact you within 5 days after the event if you win the llama. |
|
|
|
|
|
|
|
